Fig. 5From: Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) databaseVenn diagram for the screening of all PTs based on the results of the four algorithmsBack to article page